Danone S.A.'s (EPA:BN) Popularity With Investors Is Under Threat From Overpricing
Danone S.A.'s (EPA:BN) price-to-earnings (or "P/E") ratio of 25.9x might make it look like a strong sell right now compared to the market in France, where around half of the companies have P/E ratios below 16x and even P/E's below 10x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/E.
Danone certainly has been doing a good job lately as it's been growing earnings more than most other companies. The P/E is probably high because investors think this strong earnings performance will continue. If not, then existing shareholders might be a little nervous about the viability of the share price.
Check out our latest analysis for Danone
What Are Growth Metrics Telling Us About The High P/E?
There's an inherent assumption that a company should far outperform the market for P/E ratios like Danone's to be considered reasonable.
Retrospectively, the last year delivered an exceptional 83% gain to the company's bottom line. As a result, it also grew EPS by 17% in total over the last three years. Therefore, it's fair to say the earnings growth recently has been respectable for the company.
Turning to the outlook, the next three years should generate growth of 14% per year as estimated by the analysts watching the company. Meanwhile, the rest of the market is forecast to expand by 13% per annum, which is not materially different.
With this information, we find it interesting that Danone is trading at a high P/E compared to the market. Apparently many investors in the company are more bullish than analysts indicate and aren't willing to let go of their stock right now. Although, additional gains will be difficult to achieve as this level of earnings growth is likely to weigh down the share price eventually.
The Key Takeaway
We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.
Our examination of Danone's analyst forecasts revealed that its market-matching earnings outlook isn't impacting its high P/E as much as we would have predicted. Right now we are uncomfortable with the relatively high share price as the predicted future earnings aren't likely to support such positive sentiment for long. Unless these conditions improve, it's challenging to accept these prices as being reasonable.
Plus, you should also learn about this 1 warning sign we've spotted with Danone.
Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a low P/E.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:BN
Danone
Operates in the food and beverage industry in Europe, Ukraine, North America, China, North Asia, the Oceania, Latin America, rest of Asia, Africa, Turkey, the Middle East, and the Commonwealth of Independent States.
Established dividend payer and good value.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets
Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Investment Analysis (May 2026)
Recently Updated Narratives

Once In A Life Time Deeply Discounted Recession Proof Utility

SSAB in pole position when it comes to the combination of steel tariffs and the EU's investment drive
Investor Thesis: Why XPLR Infrastructure Could Be Deeply Undervalued in an AI Power Cycle
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Honeywell - The Demand-Side of the AI Infrastructure
Trending Discussion
It's wonderful. It has greatly helped me take informed decisions.
